Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective

IF 2.9 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of Medical Economics Pub Date : 2024-07-27 DOI:10.1080/13696998.2024.2385191

Keruo Zhou, Min Zhang, Chenyu Zuo, Xiazhen Xie, Jianwei, Xuan

引用次数: 0

Abstract

Objectives: To evaluate the cost-effectiveness of budesonide/formoterol reliever and maintenance therapy compared with salmeterol/fluticasone plus salbutamol as reliever therapy for asthma patients...

查看原文本刊更多论文

从中国社会角度分析布地奈德/福莫特罗 SMART疗法与沙美特罗/氟替卡松加按需SABA疗法对≥12岁中度哮喘患者的成本效益分析

目的评估布地奈德/福莫特罗缓解和维持疗法与沙美特罗/氟替卡松加沙丁胺醇作为哮喘患者缓解疗法的成本效益...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Economics HEALTH CARE SCIENCES & SERVICES-MEDICINE, GENERAL & INTERNAL

CiteScore

4.50

自引率

4.20%

发文量

122

期刊介绍： Journal of Medical Economics'' mission is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The aim of Journal of Medical Economics is to serve the information needs of the pharmacoeconomics and healthcare research community, to help translate research advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication. Journal of Medical Economics publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience